RECRUITINGOBSERVATIONAL
A Long-term Follow up Study of EXG102-031 in Participants With wAMD
A Long-term Follow-up Study to Evaluate the Injection of EXG102-031 Ophthalmic Injection in Participants With Wet Age-related Macular Degeneration (wAMD).
About This Trial
This is a long-term, safety and efficacy follow-up study of patients in the EXG102-031-111 gene therapy clinical trial for wAMD. Patients will complete visits from the parent study, and then into this long-term follow-up study for continuous safety monitoring for up to 5 years.
Who May Be Eligible (Plain English)
Who May Qualify:
1. Previously received treatment with EXG102-031 in the study (EXG102-031-111);
2. Paticipantes are willing to sign a consent form and willingness to follow protocol procedures.
Who Should NOT Join This Trial:
1\. Paticipantes are unwilling or unable to participate in long-term follow-up
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
1. Previously received treatment with EXG102-031 in the study (EXG102-031-111);
2. Paticipantes are informed consent and willingness to follow protocol procedures.
Exclusion Criteria:
1\. Paticipantes are unwilling or unable to participate in long-term follow-up
Treatments Being Tested
OTHER
No intervention, only for observational studies
No intervention, only for observational studies
Locations (1)
Peking University People's Hospital
Beijing, China